Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.63 USD 0.37%
Market Cap: 4.9B USD

Alkermes Plc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alkermes Plc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Alkermes Plc
NASDAQ:ALKS
Operating Income
$358.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Operating Income
-$28.7m
CAGR 3-Years
16%
CAGR 5-Years
-6%
CAGR 10-Years
12%
Prothena Corporation PLC
NASDAQ:PRTA
Operating Income
-$222.2m
CAGR 3-Years
-11%
CAGR 5-Years
-16%
CAGR 10-Years
-12%
M
Mural Oncology PLC
NASDAQ:MURA
Operating Income
-$138.3m
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Alkermes Plc
Glance View

Alkermes Plc, an Irish biopharmaceutical company, has carved its niche at the intersection of neuroscience and oncology, a strategic pivot that underscores its commitment to addressing unmet medical needs. The firm's focus lies in the development of innovative pharmaceuticals that offer hope and efficacy where other treatments may fall short. These include proprietary products as well as collaborations with more established pharmaceutical entities. At the heart of Alkermes' operations is its R&D engine, which drives the development of cutting-edge treatments leveraging the company's proprietary technology platforms. This not only underpins its internal drug development pipeline but also enhances its value proposition in collaborations with partner companies, fostering a symbiotic environment where innovation and mutual benefit intersect. The way Alkermes generates revenue is multifaceted, reflecting its dynamic business model. The company earns through product sales from its proprietary medicines, which are tailored for chronic diseases such as schizophrenia, addiction, and multiple sclerosis. Moreover, a significant portion of its income is derived from strategic collaborations and royalty agreements, where it grants larger pharmaceutical companies access to its technology platforms or the commercial rights to certain drug formulations. These alliances often entail milestone-based payments and ongoing royalties contingent upon sales performance, providing Alkermes with a steady revenue stream and reducing its dependency on the success of any single product. By balancing its own product development with these partnerships, Alkermes secures financial robustness while maintaining its position at the forefront of pharmaceutical innovation.

ALKS Intrinsic Value
HIDDEN
Show

See Also

What is Alkermes Plc's Operating Income?
Operating Income
358.9m USD

Based on the financial report for Sep 30, 2025, Alkermes Plc's Operating Income amounts to 358.9m USD.

What is Alkermes Plc's Operating Income growth rate?
Operating Income CAGR 1Y
-18%

Over the last year, the Operating Income growth was -18%.

Back to Top